CervoMed Inc. (CRVO)

Market Cap	18.41M
Revenue (ttm)	10.07M
Net Income (ttm)	-11.95M
Shares Out	8.25M
EPS (ttm)	-1.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	361,739
Open	2.230
Previous Close	2.230
Day's Range	2.070 - 2.280
52-Week Range	1.800 - 26.380
Beta	n/a
Analysts	Buy
Price Target	38.75 (+1,637.67%)
Earnings Date	Nov 12, 2024

About CRVO

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: CRVO
• Website: https://www.cervomed.com

Analyst Forecast

According to 8 analysts, the average rating for CRVO stock is "Buy." The 12-month stock price forecast is $38.75, which is an increase of 1,637.67% from the latest price.

Price Target

$38.75

(1,637.67% upside)

Analyst Consensus: Buy